LT2767537T - Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai - Google Patents

Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai

Info

Publication number
LT2767537T
LT2767537T LTEP14154664.8T LT14154664T LT2767537T LT 2767537 T LT2767537 T LT 2767537T LT 14154664 T LT14154664 T LT 14154664T LT 2767537 T LT2767537 T LT 2767537T
Authority
LT
Lithuania
Prior art keywords
parp
adp
ribose
polymerase
poly
Prior art date
Application number
LTEP14154664.8T
Other languages
English (en)
Inventor
Bing Wang
Daniel Chu
Original Assignee
Medivation Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies, Inc. filed Critical Medivation Technologies, Inc.
Publication of LT2767537T publication Critical patent/LT2767537T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
LTEP14154664.8T 2008-08-06 2009-07-27 Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai LT2767537T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US15103609P 2009-02-09 2009-02-09
US17308809P 2009-04-27 2009-04-27

Publications (1)

Publication Number Publication Date
LT2767537T true LT2767537T (lt) 2017-08-10

Family

ID=41129519

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14154664.8T LT2767537T (lt) 2008-08-06 2009-07-27 Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai
LTPA2019522C LTC2767537I2 (lt) 2008-08-06 2019-12-05 Poli(ADP-ribozės)polimerazės (PARP) dihidropiridoftalazinono inhibitoriai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2019522C LTC2767537I2 (lt) 2008-08-06 2019-12-05 Poli(ADP-ribozės)polimerazės (PARP) dihidropiridoftalazinono inhibitoriai

Country Status (31)

Country Link
US (7) US8012976B2 (lt)
EP (3) EP2326650B9 (lt)
JP (3) JP5984389B2 (lt)
KR (1) KR101846029B1 (lt)
CN (3) CN103896942A (lt)
AR (1) AR072970A1 (lt)
AU (1) AU2009279944B2 (lt)
BR (1) BRPI0917119B1 (lt)
CA (1) CA2732797C (lt)
CY (3) CY1115022T1 (lt)
DK (2) DK2326650T3 (lt)
ES (2) ES2466565T3 (lt)
FR (1) FR19C1071I2 (lt)
GB (1) GB2462361A (lt)
HK (2) HK1157755A1 (lt)
HR (1) HRP20170982T1 (lt)
HU (2) HUE035295T2 (lt)
IL (1) IL211070A (lt)
LT (2) LT2767537T (lt)
LU (1) LUC00140I2 (lt)
MX (1) MX2011001328A (lt)
NL (1) NL301021I2 (lt)
NO (1) NO2019042I1 (lt)
NZ (1) NZ591166A (lt)
PL (2) PL2326650T3 (lt)
PT (2) PT2767537T (lt)
SG (2) SG10201809895YA (lt)
SI (2) SI2326650T1 (lt)
TW (2) TW201422617A (lt)
WO (1) WO2010017055A2 (lt)
ZA (1) ZA201100897B (lt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201809895YA (en) * 2008-08-06 2018-12-28 Medivation Tech Llc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
CN102869258A (zh) * 2010-02-03 2013-01-09 生物马林药物股份有限公司 用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
CA2788114C (en) * 2010-02-08 2018-11-06 Biomarin Pharmaceutical Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011143426A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20190120458A (ko) * 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
MX2014003785A (es) 2011-09-30 2014-07-24 Vertex Phamaceuticals Inc Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
EP2940017B1 (en) 2011-09-30 2019-08-28 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of ATR kinase
JP5913631B2 (ja) * 2011-12-31 2016-05-11 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ピリドフタラジノン
CN106220635B (zh) 2011-12-31 2019-03-08 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
KR20220137154A (ko) 2012-01-20 2022-10-11 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
NZ700580A (en) 2012-04-05 2016-07-29 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
EP3174855B1 (en) * 2014-07-31 2023-05-10 Medivation Technologies LLC Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN107922425B (zh) 2015-08-25 2021-06-01 百济神州有限公司 制备parp抑制剂、结晶形式的方法及其用途
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
EP3519051B1 (en) * 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
TW201840564A (zh) 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
CN110650961B (zh) * 2017-05-08 2022-09-27 广州丹康医药生物有限公司 Parp抑制剂、其药物组合物、制备方法和应用
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
JP2020536887A (ja) 2017-10-13 2020-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及***
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
US20220227757A1 (en) 2019-05-14 2022-07-21 Suzhou Four Health Pharmaceuticals Co., Ltd. Quinazoline-2,4-dione derivatives as parp inhibitors
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
CA3201467A1 (en) 2020-11-13 2022-05-19 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
MX2023006768A (es) 2020-12-07 2023-06-19 Pfizer Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo.
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
AU2022253474A1 (en) * 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2023239789A1 (en) * 2022-06-08 2023-12-14 Valo Health, Inc. Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
CN116283924A (zh) * 2023-01-16 2023-06-23 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) * 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
NZ534712A (en) 2002-02-19 2006-11-30 Ono Pharmaceutical Co Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1582520A1 (en) * 2002-11-12 2005-10-05 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
CA2517629C (en) 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004242947B2 (en) * 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
KR20070027504A (ko) 2004-02-18 2007-03-09 아스트라제네카 아베 테트라졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
WO2010017850A1 (de) 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von cycloalkyl-substituierten piperazinverbindungen
JP2010536807A (ja) 2007-08-22 2010-12-02 ４エスツェー アクチェンゲゼルシャフト キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン
CN102083314B (zh) * 2007-10-03 2014-04-30 卫材股份有限公司 Parp抑制剂化合物、组合物以及使用方法
CN101998959B (zh) 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
SG10201809895YA (en) 2008-08-06 2018-12-28 Medivation Tech Llc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN102869258A (zh) 2010-02-03 2013-01-09 生物马林药物股份有限公司 用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
CA2788114C (en) 2010-02-08 2018-11-06 Biomarin Pharmaceutical Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
KR20190120458A (ko) * 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EP3174855B1 (en) 2014-07-31 2023-05-10 Medivation Technologies LLC Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Also Published As

Publication number Publication date
TW201422617A (zh) 2014-06-16
HUS1900053I1 (hu) 2020-02-28
US9820985B2 (en) 2017-11-21
JP2011530513A (ja) 2011-12-22
US20200261454A1 (en) 2020-08-20
NL301021I1 (nl) 2019-12-18
PL2767537T3 (pl) 2017-09-29
JP5984389B2 (ja) 2016-09-06
CY2019044I1 (el) 2020-05-29
RU2011108493A (ru) 2012-09-20
JP2015157843A (ja) 2015-09-03
ES2466565T3 (es) 2014-06-10
CN103896942A (zh) 2014-07-02
NZ591166A (en) 2012-11-30
PT2767537T (pt) 2017-07-17
EP2326650B9 (en) 2014-09-10
LUC00140I2 (lt) 2021-02-12
EP2767537A1 (en) 2014-08-20
MX2011001328A (es) 2011-04-04
PT2326650E (pt) 2014-05-06
HUE035295T2 (en) 2018-05-02
WO2010017055A2 (en) 2010-02-11
EP3241832A1 (en) 2017-11-08
US20180117045A1 (en) 2018-05-03
US11364241B2 (en) 2022-06-21
US20210069191A1 (en) 2021-03-11
TWI448464B (zh) 2014-08-11
IL211070A0 (en) 2011-04-28
CN104478875A (zh) 2015-04-01
CN104478875B (zh) 2017-04-12
LTC2767537I2 (lt) 2020-11-10
CN102171214A (zh) 2011-08-31
EP2767537B1 (en) 2017-04-12
HK1157755A1 (en) 2012-07-06
AU2009279944A1 (en) 2010-02-11
WO2010017055A3 (en) 2010-05-27
US10543209B2 (en) 2020-01-28
NO2019042I1 (no) 2019-11-28
PL2326650T3 (pl) 2014-07-31
US8999987B2 (en) 2015-04-07
DK2326650T3 (en) 2014-03-10
GB2462361A (en) 2010-02-10
US20150209357A1 (en) 2015-07-30
SI2767537T1 (sl) 2017-08-31
TW201018688A (en) 2010-05-16
HRP20170982T1 (hr) 2017-09-22
FR19C1071I1 (lt) 2020-01-17
US20130190306A1 (en) 2013-07-25
FR19C1071I2 (fr) 2020-10-16
CY1119218T1 (el) 2018-02-14
DK2767537T3 (da) 2017-06-19
SI2326650T1 (sl) 2014-04-30
HK1200813A1 (en) 2015-08-14
CA2732797A1 (en) 2010-02-11
EP2326650A4 (en) 2012-03-21
LUC00140I1 (lt) 2019-12-13
US10780088B2 (en) 2020-09-22
US8012976B2 (en) 2011-09-06
CA2732797C (en) 2017-01-03
CN102171214B (zh) 2015-06-24
CY1115022T1 (el) 2016-12-14
JP2018012698A (ja) 2018-01-25
LTPA2019522I1 (lt) 2019-12-27
ZA201100897B (en) 2012-06-27
US20110237581A1 (en) 2011-09-29
IL211070A (en) 2014-11-30
BRPI0917119A2 (pt) 2015-11-17
EP2326650A2 (en) 2011-06-01
EP2326650B1 (en) 2014-02-26
GB0913474D0 (en) 2009-09-16
SG193842A1 (en) 2013-10-30
US8420650B2 (en) 2013-04-16
RU2514937C2 (ru) 2014-05-10
NL301021I2 (nl) 2020-04-14
ES2625817T3 (es) 2017-07-20
US20100035883A1 (en) 2010-02-11
BRPI0917119B1 (pt) 2021-07-13
AU2009279944B2 (en) 2014-09-11
KR101846029B1 (ko) 2018-04-06
KR20110040973A (ko) 2011-04-20
AR072970A1 (es) 2010-10-06
SG10201809895YA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
HUS1900053I1 (hu) A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai
HUS1800022I1 (hu) Amid-szubsztituált indazol-származékok mint poli(ADP-ribóz)-polimeráz (PARP) inhibitorok
IL213993A0 (en) Poly (adp-ribose) polymerase (parp) inhibitors
HK1194922A1 (en) Inhibitors of poly(adp-ribose)polymerase (adp-)
EP2247600A4 (en) BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
ZA200903996B (en) Inhibitors of poly (adp-ribose)polymerase
GB0806912D0 (en) Polymerase inhibitors
GB0806914D0 (en) Polymerase inhibitors
GB0806915D0 (en) Polymerase inhibitors
GB0806919D0 (en) Polymerase inhibitors
GB0806920D0 (en) Polymerase inhibitors
GB0806913D0 (en) Polymerase inhibitors
GB0806917D0 (en) Polymerase inhibitors
GB0806911D0 (en) Polymerase inhibitors